-
Evercore ISI Starts Forte Biosciences Inc. (FBRX) at Outperform
-
Forte Biosciences (FBRX) Misses Q3 EPS by 99c
-
Guggenheim Starts Forte Biosciences Inc. (FBRX) at Buy, PT $75
-
Forte Biosciences Inc. (FBRX) PT Lowered to $54 at Brookline Capital Markets
-
Forte Biosciences (FBRX) Misses Q2 EPS by 96c
-
Forte Biosciences (FBRX) Announces Proposed Share Offering
-
Forte Biosciences (FBRX) Announces Positive Data in FB102 Celiac Disease Phase 1B Study
-
Forte Biosciences (FBRX) Misses Q1 EPS by 137c
-
Forte Biosciences (FBRX) Files $300M Mixed Shelf
-
TD Cowen Starts Forte Biosciences Inc. (FBRX) at Buy
-
Forte Biosciences (FBRX) Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
-
Forte Biosciences (FBRX) Misses Q3 EPS by 433c

